Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Newly Diagnosed High Risk Pediatric ALL
NCT02339350Phase 2Unknown
- Sponsor
- Korean Society of Pediatric Hematology-Oncology
- Start
- Jan 2015
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Korean Society of Pediatric Hematology-Oncology. Primary endpoint: Event-Free Survival at 5 years. Status: unknown.
02
Drugs
methotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02339350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339350.